

## P R O D U C T I N S E R T

**SSP Wipe Test**

Catalog #SSPWT12

**For Research Use Only. Not for use in diagnostic procedures.****SUMMARY AND EXPLANATION**

The Wipe Test allows the user to assure that the laboratory work area is not contaminated by carry-over of amplification product.

The Wipe Test primer set amplifies the internal control amplicon generated in the One Lambda Micro SSPTM Typing Trays. The internal control PCR product amplified from the human  $\beta$ -globin gene is the most likely contaminating PCR product due to its amplification in every well.

Since each laboratory has its own method to test for contamination, One Lambda does not recommend any specific protocol and provides only the formulation needed to run a test.

**REAGENTS****A. Warning or Caution**

1. **Warning:** Use only the D-Mix purchased with this One Lambda SSP Wipe Test.
2. **Biohazard Warning:** The ethidium bromide used for staining of DNA is a potential carcinogen. Always wear gloves when handling stained gels.
3. **Biohazard Warning:** All blood products should be treated as potentially infectious.
4. **Caution:** Wear UV-blocking eye protection, and do not view UV light source directly when viewing or photographing gels.
5. Pipettes used for Post-PCR manipulations should not be used for Pre-PCR manipulations.
6. If salts have precipitated out of solution in the D-mix aliquots during shipping or storage, re-dissolve by extended vortexing at room temperature.

**B. Instructions for Use (See Directions for Use Below)****C. Storage Instructions**

Store reagents at temperature indicated on label. Use before expiration date.

**INSTRUMENT REQUIREMENTS**

The following program is designed for use on 96-Well GeneAmp® PCR System 9600, 9700 or Veriti™ 96-Well Thermal Cycler (Applied Biosystems). Set ramp speed to 9600 for 96-Well GeneAmp® PCR System 9700. Set ramp speed to 9600 Emulation Mode for Veriti™ 96-Well Thermal Cycler. Set reaction volume to 10  $\mu$ l. Program your thermal cycler before starting the "Directions for Use."

| # of Cycles | Step | Temp (°C) | Time (sec) |
|-------------|------|-----------|------------|
| 1           | 1    | 96        | 130        |
|             | 2    | 63        | 60         |
|             |      |           |            |
| 9           | 1    | 96        | 10         |
|             | 2    | 63        | 60         |
|             |      |           |            |
| 20          | 1    | 96        | 10         |
|             | 2    | 59        | 50         |
|             | 3    | 72        | 30         |
|             |      |           |            |
| End         | 1    | 4         | ---        |

**PROCEDURE****A. Materials Provided (100 tests)**

1. 200 µl primer (2µl per test)
2. 1000 µl D-mix (7 µl per test)

***Note:** The volumes provided are slightly more than the amount required for testing. This is to account for inadvertent losses which may result from pipetting.*

**B. Materials Required, but Not Provided**

Taq polymerase

**C. Step-by-Step Procedure**

See **Directions for Use** below.

**DIRECTIONS FOR USE:**

Use the following formulation to prepare the reagents for your wipe test:

1. Use 2µl of wipe test primer set per PCR reaction.
2. Use 1µl of the test sample and 7 µl wipe test D-mix per reaction.
3. Use .05 µl at 5 units/µl of recombinant taq polymerase per reaction.
4. Perform standard PCR with the Micro SSP™ PCR program (OLI-1) as specified below.

**TRADEMARKS USED IN THIS DOCUMENT/PRODUCT**

|                     |                        |
|---------------------|------------------------|
| Micro SSP™          | One Lambda Inc.        |
| GeneAmp®            | Hoffman-La Roche, Inc. |
| Fotodyne FOTO/UV®21 | FOTODYNE Incorporated  |
| FMC SeaKem®         | FMC Corporation        |
| ARMS™               | Zeneca Limited         |

**PATENTS USED IN THIS DOCUMENT**

Notice to purchaser of licensed product: The purchase price of this product includes limited, non-transferable rights under U.S. Patents 4,683,202, 4,683,195 and 4,965,188 and their foreign counterparts, owned by Roche Molecular Systems, Inc. and F. Hoffmann-LaRoche Ltd (“Roche”), to use only this amount of the product to practice the Polymerase Chain Reaction (“PCR”) Process described in said patents solely for the HLA Typing applications of the purchaser solely for organ, bone marrow, or tissue transplantation, and explicitly excludes analysis of forensic evidence or parentage determination. The right to use this product to perform and to offer commercial services for HLA Typing for organ or tissue transplantation using PCR, including reporting the results of the purchaser’s activities for a fee or other commercial consideration, is also hereby granted. Further information on purchasing licenses to practice PCR may be obtained by contacting, in the United States, the Director of Licensing at Roche Molecular Systems, Inc., 1145 Atlantic Avenue, Alameda, California 94501, and outside the United States, the PCR Licensing Manager, F. Hoffmann-La Roche Ltd, Grenzacherstr.124, CH-4070 Basel, Switzerland.

SSP technology is licensed from Zeneca Limited, through its Zeneca Diagnostics business, Blacklands Way, Abingdon Business Park, Abingdon, Oxfordshire, England OX14 IDY and covered under the following patents held by Zeneca Corporation: European Patent No. 0 332 435 B1, United States Patent No. 5,595,890, entitled “Method of detecting nucleotide sequences,” and Canadian Patent No. 1323592, and corresponding patents and patent applications worldwide.

The Micro SSPTM DNA typing reagents are manufactured and distributed by One Lambda, Inc., 22801 Roscoe Blvd. West Hills, CA 91304 USA

## REVISION HISTORY

| Revision | Date       | Revision Description                                                                 |
|----------|------------|--------------------------------------------------------------------------------------|
| 01       | 04/08/2019 | Upgraded Internal Document Control System. No changes to the document content.       |
| 02       | 06/20/2019 | Correct Regulatory designation to Research Use Only                                  |
| 03       | Current    | Updated contact information and address to reflect change in legal manufacture site. |